Original Article

Incidence, Burden, and Trend of Cutaneous Leishmaniasis over Four Decades in Iran


Background: Iran is among the first six countries in the world with the highest annual incidence of cutaneous leishmaniasis. This study aimed at estimating the incidence, burden, and trend of cutaneous leishmaniasis at the national level in Iran from 1977 to 2015.

Methods: This study was conducted in 2017, used Disability Adjusted Life Years (DALYs) index, recommended by the WHO for assessing the Global Burden of Diseases, to estimate the burden of cutaneous leishmaniasis. The data on the incidence of the disease and the number of cases was obtained from the communicable diseases surveillance system (Center for Communicable Diseases Control (CCDC), Ministry of Health and Medical Education (MOHME) of Iran) that routinely collects data from all over the country; in addition, some data was extracted by reviewing the texts. Considering the views expressed in a panel of experts, to calculate the actual incidence of the disease, the number of registered cases was multiplied by 5.

Results: The incidence of cutaneous leishmaniasis varied from approximately 50 to 250 cases per 100,000 population during the studied period. During these years, the incidence of the disease was higher in males than females. Moreover, the burden of cutaneous leishmaniasis varied between 1.18 and 5.7 DALYs per 100000 population during the studied period. The incidence and burden of cutaneous leishmaniasis have not significantly decreased in recent years.

Conclusion: Despite the implementation of a program for controlling cutaneous leishmaniasis in Iran since 1977, the incidence and burden of the disease are still high in the country; it is seriously alarming for policy makers and managers of the health system in Iran, indicating the presence of some problems in controlling the disease.


1. Ministry of Health and Medical Education (2012). National Guideline for Cutaneous Leishmaniasis in Iran. Ministry of Health and Medical Education. Health Deputy. Center of Communicable Diseases Control. Zoonoses Office, Tehran, Iran.
2. World Health Organization (2018). Leishmaniasis. Media Centre. World Health Organization. http://www.who.int/mediacentre/factsheets/fs375/en/
3. Meireles CB, Maia LC, Soares GC et al (2017). Atypical presentations of cutaneous leishmaniasis: a systematic review. Acta Trop, 172:240-54.
4. World Health Organization (2017). Global Health Observatory data repository. Leishmaniasis. World Health Organization. http://apps.who.int/gho/data/node.main.NTDLEISH?lang=en%5d%20Accessed
5. Mitropoulos P, Konidas P, Durkin-Konidas M (2010). New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol, 63(2):309-22.
6. Razmjou S, Hejazy H, Motazedian MH et al (2009). A new focus of zoonotic cutaneous leishmaniasis in Shiraz, Iran. Trans R Soc Trop Med Hyg, 103(7):727-30.
7. Shirzadi M, Esfahania S, Mohebalia M et al (2015). Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012/Situation epidemiologique de la leishmaniose en Republique Islamique d'Iran, 1983-2012. East Mediterr Health J, 21(10):736-42.
8. Heydarpour F, Sari AA, Mohebali M et al (2016). Incidence and Disability-Adjusted Life Years (Dalys) Attributable to Leishmaniasis In Iran, 2013. Ethiop J Health Sci, 26(4):381-8.
9. Murray CJ, Vos T, Lozano R et al (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859):2197-223.
10. Murray CJ, Ezzati M, Flaxman AD et al (2012). GBD 2010: design, definitions, and metrics. Lancet, 380(9859):2063-6.
11. Salomon JA, Vos T, Hogan DR et al (2012). Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, 380(9859):2129-43.
12. Dicker D, Nguyen G, Abate D et al (2018). Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392(10159):1684-735.
13. Abubakar I, Tillmann T, Banerjee A (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963):117-71.
14. Vos T, Abajobir AA, Abate KH et al (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390(10100):1211-59.
15. Murray CJ, Barber RM, Foreman KJ et al (2015). Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, 386(10009):2145-91.
16. Iran Statistical Yearbook (2016). Statistical Center of Iran. https://www.amar.org.ir/english/Iran-Statistical-Yearbook
17. World Health Organization (2017). Leishmaniasis Country Profiles. Iran (Islamic Republic of). World Health Organization. http://www.who.int/leishmaniasis/burden/Leishmaniasis_Iran/en/
18. Kassiri H, Shemshad K, Shojaee S (2013). The incidence rate of cutaneous leishmaniasis in Behbahan County of Khuzestan Province, Southwest of Iran. Jundishapur Journal of Microbiology, 6: e7045.
IssueVol 48 No Supple 1 (2019) QRcode
SectionOriginal Article(s)
Cutaneous leishmaniasis Incidence Disability adjusted life year (DALY) Burden Iran

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
PIROOZI B, MORADI G, ALINIA C, MOHAMADI P, GOUYA MM, NABAVI M, GHARACHORLOO F, KHADEM ERFAN MB, SHIRZADI MR. Incidence, Burden, and Trend of Cutaneous Leishmaniasis over Four Decades in Iran. Iran J Public Health. 2019;48(Supple 1):28-35.